HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REACH Requirements Eased For Certain Chemicals Under Amendment

This article was originally published in The Rose Sheet

Executive Summary

The European Parliament Environment Committee is recommending an amendment easing registration requirements for chemicals produced in quantities between one and ten tons under the REACH chemicals program. The committee adopted a report with a large number of amendments Oct. 4 by a vote of 40-19, with two abstentions

You may also be interested in...



CTFA Promotes Drug Harmonization Model For Cosmetics Industry

The cosmetics industry should adopt the International Conference on Harmonisation model as part of its global harmonization efforts, Cosmetic, Toiletry and Fragrance Association VP-International Lou Santucci said during a presentation at the Health & Beauty America conference Sept. 27-29 in New York City

EU Chemical Plan Overhaul Exempts Polymers, Reduces Burden Downstream

The European Commission's 1chemical testing proposal released Oct. 29 includes provisions to exempt certain polymers and reduce the burden on downstream users in an effort to address industry concerns

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel